Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Parasitol Res. 2012 Feb;110(2):895-9. doi: 10.1007/s00436-011-2573-3. Epub 2011 Aug 9.
The increasing spread of chloroquine resistant malaria has intensified the search for new antimalarial treatment, especially drugs that can be used in combination. Ciprofloxacin (CFX) a fluoroquinolone commonly used to treat bacterial infections has been shown to possess significant antimalarial activity both in vitro and in vivo. Thus efforts in this study were devoted to evaluating the antimalarial activity of combination of chloroquine (CQ) with varying doses (10, 20, 40 80, 160 mg/kg body weight) of CFX in groups of 35 mice inoculated intraperitoneally with 10(7) chloroquine resistant strain Plasmodium berghei ANKA. Parasitological activity and survival of the animals were assessed over 21 days. Parasitemia in non-treated control mice peaked at 78% on day 9 and none survived by day 10. However, the combination of CQ with 160 mg/kg body weight of CFX resulted in a reduction in parasitemia between days 9 and 14 and this was significantly lower than that obtained with CQ alone or CQ combined with the lower doses of CFX (p < 0.05). In addition, the combination of CQ with 160 mg/kg CFX significantly reduced mortality in the infected animals (p = 0.0002) compared with the other treatment groups. The results from this study support the potential usefulness of CFX in combination with antimalarial drugs for the treatment of chloroquine resistant human malaria.
耐氯喹疟疾的传播不断加剧,促使人们加紧寻找新的抗疟治疗方法,尤其是可以联合用药的药物。环丙沙星(CFX)是一种常用于治疗细菌感染的氟喹诺酮类药物,其在体外和体内均显示出显著的抗疟活性。因此,本研究的重点是评估不同剂量(10、20、40、80、160mg/kg 体重)的 CFX 与氯喹(CQ)联合应用对腹腔接种 10(7)耐氯喹疟原虫伯氏疟原虫 ANKA 的 35 只小鼠的抗疟活性。在 21 天内评估寄生虫学活性和动物的存活率。未经治疗的对照组小鼠的疟原虫血症在第 9 天达到 78%的峰值,第 10 天无存活者。然而,CQ 与 160mg/kg 体重的 CFX 联合使用可使第 9 天至第 14 天的疟原虫血症减少,且与单独使用 CQ 或与较低剂量 CFX 联合使用 CQ 相比,差异有统计学意义(p<0.05)。此外,CQ 与 160mg/kg CFX 联合使用与其他治疗组相比,可显著降低感染动物的死亡率(p=0.0002)。本研究结果支持 CFX 与抗疟药物联合用于治疗耐氯喹的人类疟疾具有潜在的有效性。